KALA BIO Dirección
Dirección controles de criterios 2/4
El CEO de KALA BIO's es Mark Iwicki , nombrado en Sep 2015, tiene una permanencia de 8.58 años. compensación anual total es $1.87M, compuesta por 36.5% salario y 63.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.48% de las acciones de la empresa, por valor de $89.46K. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 6.6 años, respectivamente.
Información clave
Mark Iwicki
Chief Executive Officer (CEO)
US$8.3m
Compensación total
| Porcentaje del salario del CEO | 8.5% |
| Permanencia del CEO | 8.7yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 6yrs |
| Promedio de permanencia en la Junta Directiva | 6.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Apr 05Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?
Mar 08What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?
Feb 15How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?
Jan 25
If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today
Jan 04Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec 23The Play On Kala Pharmaceuticals
Dec 17Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?
Dec 14How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?
Nov 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$8m | US$709k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$2m | US$682k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$80m |
| Jun 30 2022 | n/a | n/a | -US$137m |
| Mar 31 2022 | n/a | n/a | -US$145m |
| Dec 31 2021 | US$3m | US$644k | -US$143m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$113m |
| Dec 31 2020 | US$5m | US$586k | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$91m |
| Dec 31 2019 | US$3m | US$564k | -US$94m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$90m |
| Mar 31 2019 | n/a | n/a | -US$81m |
| Dec 31 2018 | US$3m | US$535k | -US$67m |
| Sep 30 2018 | n/a | n/a | -US$53m |
| Jun 30 2018 | n/a | n/a | -US$47m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | US$2m | US$501k | -US$42m |
Compensación vs. Mercado: La compensación total de Mark($USD1.87M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Mark ha aumentado mientras la empresa no es rentable.
CEO
Mark Iwicki (57 yo)
8.7yrs
Permanencia
US$8,342,714
Compensación
Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 8.7yrs | US$8.34m | 0.48% $ 94.6k | |
| President & COO | 6.5yrs | US$2.94m | 0.17% $ 34.0k | |
| Head of R&D and Chief Medical Officer | 11.3yrs | US$2.92m | 0.20% $ 38.5k | |
| Founder & Chair of the Scientific Advisory Board | no data | sin datos | sin datos | |
| CFO & Treasurer | 10.3yrs | sin datos | 0.15% $ 29.9k | |
| Executive Director of Investor Relations & Corporate Communications | 2.8yrs | sin datos | sin datos | |
| Senior VP of Manufacturing & Supply Chain Management | 6.8yrs | sin datos | sin datos | |
| Chief Business Officer | 2.5yrs | sin datos | 0.52% $ 101.8k | |
| Chief Medical Advisor | 1.2yrs | sin datos | sin datos | |
| Senior VP & Corporate Controller | 2.1yrs | sin datos | sin datos | |
| Executive Director of Account Management | 6yrs | sin datos | sin datos | |
| Executive Director of Trade & Alternate Channels | 6yrs | sin datos | sin datos |
6.0yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KALA es experimentado (6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 9.1yrs | US$8.34m | 0.48% $ 94.6k | |
| Founder & Chair of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Board Observer | 8.1yrs | sin datos | sin datos | |
| Independent Director | 6.3yrs | US$302.01k | 0.062% $ 12.1k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Lead Independent Director | 6.7yrs | US$402.36k | 0.078% $ 15.2k | |
| Independent Director | 2.5yrs | US$234.09k | 0.23% $ 44.7k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.6yrs | US$236.94k | 0.045% $ 8.8k | |
| Independent Director & Member of Advisory Board | 10.3yrs | US$392.20k | 0.0093% $ 1.8k |
6.7yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de KALA se considera experimentada (6.6 años de antigüedad promedio).